CVGENES-AT-TARGET

Exploitation of genomic variants affecting coronary artery disease and stroke risk for therapeutic intervention

 Coordinatore DEUTSCHES HERZZENTRUM MUNCHEN 

 Organization address address: Lazarettstrasse 36
city: MUNICH
postcode: 80636

contact info
Titolo: Mr.
Nome: Per
Cognome: Larsen
Email: send email
Telefono: +49 89 12181791
Fax: +49 89 1218 4083

 Nazionalità Coordinatore Germany [DE]
 Sito del progetto http://cvgenesattarget.eu/
 Totale costo 7˙875˙614 €
 EC contributo 5˙995˙449 €
 Programma FP7-HEALTH
Specific Programme "Cooperation": Health
 Code Call FP7-HEALTH-2013-INNOVATION-1
 Funding Scheme CP-FP
 Anno di inizio 2013
 Periodo (anno-mese-giorno) 2013-10-01   -   2016-09-30

 Partecipanti

# participant  country  role  EC contrib. [€] 
1    DEUTSCHES HERZZENTRUM MUNCHEN

 Organization address address: Lazarettstrasse 36
city: MUNICH
postcode: 80636

contact info
Titolo: Mr.
Nome: Per
Cognome: Larsen
Email: send email
Telefono: +49 89 12181791
Fax: +49 89 1218 4083

DE (MUNICH) coordinator 853˙354.30
2    UNIVERSITY OF LEICESTER

 Organization address address: University Road
city: LEICESTER
postcode: LE1 7RH

contact info
Titolo: Mrs.
Nome: Marie
Cognome: Adams
Email: send email
Telefono: +44 116 252 2783
Fax: +44 116 252 2028

UK (LEICESTER) participant 825˙270.00
3    UNIVERSITAIR MEDISCH CENTRUM UTRECHT

 Organization address address: HEIDELBERGLAAN 100
city: UTRECHT
postcode: 3584 CX

contact info
Titolo: Mrs.
Nome: Karin
Cognome: Krol-Simons
Email: send email
Telefono: +31 88 755 79 08

NL (UTRECHT) participant 609˙720.00
4    FRAUNHOFER-GESELLSCHAFT ZUR FOERDERUNG DER ANGEWANDTEN FORSCHUNG E.V

 Organization address address: Hansastrasse 27C
city: MUENCHEN
postcode: 80686

contact info
Titolo: Mr.
Nome: Michael
Cognome: Prestele
Email: send email
Telefono: +49 89 1205 2738
Fax: +49 89 1205 7534

DE (MUENCHEN) participant 539˙488.30
5    LUDWIG-MAXIMILIANS-UNIVERSITAET MUENCHEN

 Organization address address: GESCHWISTER SCHOLL PLATZ 1
city: MUENCHEN
postcode: 80539

contact info
Titolo: Prof.
Nome: Martin
Cognome: Dichgans
Email: send email
Telefono: +49 8970957801

DE (MUENCHEN) participant 503˙040.00
6    4SC DISCOVERY GMBH

 Organization address address: AM KLOPFERSPITZ 19A
city: PLANEGG MARTINSRIED
postcode: 82152

contact info
Titolo: Dr.
Nome: Stefan
Cognome: Strobl
Email: send email
Telefono: +49 897007630

DE (PLANEGG MARTINSRIED) participant 454˙260.00
7    BIOCEROS BV

 Organization address address: YALELAAN 46
city: UTRECHT
postcode: 3584 CM

contact info
Titolo: Mr.
Nome: Remco
Cognome: Brandt
Email: send email
Telefono: +31 30 253 7940
Fax: +31 847309664

NL (UTRECHT) participant 446˙850.00
8    CLINICAL GENE NETWORKS AB

 Organization address address: Karolinska Sience Park - FOGDEVRETEN 2
city: STOCKHOLM
postcode: 171 77

contact info
Titolo: Prof.
Nome: Johan
Cognome: Björkegren
Email: send email
Telefono: +46 733 568181

SE (STOCKHOLM) participant 397˙748.20
9    GENEDATA AG

 Organization address address: MARGARETHENSTRASSE 38
city: BASEL
postcode: 4053

contact info
Titolo: Dr.
Nome: Timo
Cognome: Wittenberger
Email: send email
Telefono: +41 61 5118 443

CH (BASEL) participant 374˙062.50
10    THE CHANCELLOR, MASTERS AND SCHOLARS OF THE UNIVERSITY OF OXFORD

 Organization address address: University Offices, Wellington Square
city: OXFORD
postcode: OX1 2JD

contact info
Titolo: Dr.
Nome: Stephen
Cognome: Conway
Email: send email
Telefono: +44 1865 289800
Fax: +44 1865 289801

UK (OXFORD) participant 354˙560.00
11    UNIVERSITAET ZU LUEBECK

 Organization address address: RATZEBURGER ALLEE 160
city: LUEBECK
postcode: 23538

contact info
Titolo: Mrs.
Nome: Gabriele
Cognome: Huhn
Email: send email
Telefono: +49 4515004857
Fax: +49 451 500 5767

DE (LUEBECK) participant 336˙080.00
12    Horizon Discovery Limited

 Organization address address: CAMBRIDGE RESEARCH PARK
city: Cambridge
postcode: CB25 9TL

contact info
Titolo: Dr.
Nome: Charli
Cognome: Batley
Email: send email
Telefono: 44122365586
Fax: 441224000000

UK (Cambridge) participant 240˙179.20
13    EUROPEAN SCREENINGPORT GMBH

 Organization address address: SCHNACKENBURGALLEE 114
city: HAMBURG
postcode: 22525

contact info
Titolo: Dr.
Nome: Philip
Cognome: Gribbon
Email: send email
Telefono: +49 403037640
Fax: +49 40303764100

DE (HAMBURG) participant 60˙836.50

Mappa


 Word cloud

Esplora la "nuvola delle parole (Word Cloud) per avere un'idea di massima del progetto.

cad    therapeutically    fact    genomic    attractive    intervention    stroke    causal    atherosclerosis    gwa    vitro    variants    loci    treatment    mechanisms    applicants    genes    majority    risk    pathways    therapeutic    vivo   

 Obiettivo del progetto (Objective)

'Atherosclerosis and its most disabling sequelae, coronary artery disease (CAD) and stroke, are leading causes of death in Europe. Until now, preventive and therapeutic interventions for these diseases aim at ameliorating the effects of established cardiovascular risk factors. More recently, results of genome-wide association (GWA) studies added to our perception of mechanisms leading to atherosclerosis. At present, over 40 CAD and several genomic risk loci have been identified, the majority through efforts led by the applicants. Some genes at these loci work through known risk factors such as lipids and, in fact, are already established or evolving treatment targets. However, this is not true for the majority of risk variants, which implies that key pathways leading to atherosclerosis are yet to be exploited for therapeutic intervention. This EU network (CVgenes@target), which brings together an equal number of SME- and academic partners, will utilize genomic variants affecting atherosclerosis risk for identification of both underlying genes and affected pathways in order to identify, characterize, and validate novel therapeutically relevant targets for prevention and treatment of CAD and stroke. In programme 1 we will investigate molecular mechanisms at the genomic loci in order to further unravel causal genes, in programme 2 we will explore in vitro and in vivo whether the pathways disturbed by causal genes are suitable for therapeutic intervention, and in programme 3 we will establish assays and initiate high throughput screens to tackle therapeutically attractive targets. Our resources including large OMICs and state-of-the-art bioinformatics platforms as well as multiple, already established in vitro and in vivo models support the feasibility of the approach. In fact, two genomic risk loci (ADAMTS7 (CAD); HDAC9 (stroke and CAD)), both identified in GWA studies under direction of the applicants, already revealed attractive targets for therapeutic intervention.'

Altri progetti dello stesso programma (FP7-HEALTH)

FLU-PHARM (2010)

New drugs targeting influenza virus polymerase

Read More  

NOVO (2012)

Novel approaches for prevention and degeneration of pathogenic bacteria biofilms formed on medical devices e.g. catheters

Read More  

ITECH (2013)

Roadmap for Research and Innovation in Health Technology

Read More